Avigen Logo
About Avigen Research & Development Pipeline Clinical Trials Investors Contact Us

Zola Horovitz, Ph.D., Chairman of the Board, has served as a director of Avigen since November 1994. Dr. Horovitz has been an independent consultant to pharmaceutical and biotechnology companies since May 1994. From 1991 to May 1994, Dr. Horovitz served as Vice President, Business Development and Planning and from 1990 to 1991 as Vice President, Licensing at Bristol-Myers Squibb Company, a pharmaceutical and healthcare products company. Prior to this, Dr. Horovitz served from 1959 through 1989 in various positions at the Squibb Institute for Medical Research, including Vice President, Research, Planning & Scientific Liaison, Vice President, Drug Development, and Vice President, Biological and Pharmaceutical R&D. Dr. Horovitz currently serves on the board of directors of BioCryst Pharmaceuticals, Inc., Genvec, Inc., Genaera Corporation, Palatin Technologies, Inc., DOV Pharmaceutical Inc., NitroMed, Inc., and Immunicon Corporation, all of which are biotechnology companies. From 1975 through 1993 Dr. Horovitz served on the Scientific Advisory Council at Princeton University and from 1976 through 1989 he served on the Advisory Board of Rutgers University College of Pharmacy. Dr. Horovitz received a Ph.D. and an M.S. in Pharmacology and a B.S. in Pharmacy from the University of Pittsburgh.

John K.A. Prendergast, Ph.D., has served as a director of the Company since December 1992, and since September 2004 has served as our Lead Independent Director. From December 1992 to March 1996, Dr. Prendergast also served as a Vice President and the Treasurer of the Company. Dr. Prendergast is the President of SummerCloud Bay Inc., a consulting firm providing services to the biotechnology industry he founded in 1993. Dr. Prendergast is currently chairman of the board of directors of Palatin Technologies, Inc. and AVAX Technologies, Inc., both of which are biopharmaceutical companies. Dr. Prendergast also serves as a director of MediciNova, Inc., a biopharmaceutical company, and is currently serving as the executive chairman of the board of directors of Antyra, Inc., a privately held biopharmaceutical company. Dr. Prendergast received M.Sc. and Ph.D. degrees from the University of New South Wales, Sydney, Australia, and a C.S.S. in administration and management from Harvard University.

Kenneth Chahine, Ph.D., J.D., served as President and Chief Executive Officer of Avigen from March 2004 through March 2009. Dr. Chahine has been a director of Avigen since March 2004.  Dr. Chahine joined Avigen in 1998, and served first as Avigen's Vice President, Business Development and Intellectual Property, and then as Chief Operating Officer.  Prior to joining Avigen, he worked at the patent law firm of Madson & Metcalf, P.C. in Salt Lake City from 1994 to 1998.  Between 1992 and 1993, Dr. Chahine worked as a research scientist at Parke-Davis Pharmaceuticals and held a research scientist post at the University of Utah Department of Human Genetics from 1994 to 1996.  Dr. Chahine also served as the western regional news and legal correspondent for Nature Biotechnology for many years.  Dr. Chahine serves on the board of directors of the Lassonde New Venture Development Center at the University of Utah School of Business, and he is an Adjunct Professor at the University of Utah College of Law.  Dr. Chahine holds a J.D. from the University of Utah and a Ph.D. in biochemistry and molecular biology from the University of Michigan.

Richard Wallace, B.Com. (Hons), joined as a director of the Company in March 2006.  Mr. Wallace has fifteen years experience at GlaxoSmithKline (GSK) starting in 1992, spanning roles from Vice President Commercial (Canadian Pharmaceuticals), Vice President U.S. Business Development, Vice President Sales & Marketing (U.S. Oncology and HIV), Vice President Clinical Development and Product Strategy, to Senior Vice President Global Commercial Strategy. He served as a member of GSK's Research and Development Executive, Commercial Operations Committee and Product Management Board. His experience prior to joining GSK includes 8 years with Bristol Myers Squibb and 7 years at Johnson & Johnson in assignments from marketing, sales, manufacturing and general management. Mr Wallace currently serves on the board of directors of ImmunoGen Inc and Clinical Data Inc.

Mr. Wallace received B.Com. and B.Com.Honors degrees from Rhodes University, South Africa.

Jan K. Öhrström, M.D., joined the Avigen board in 2007.  Dr. Öhrström is currently Chief Operating Officer and President of ProFibrix, Inc. in Seattle, a Dutch Headquartered biotech company that develops Protein drugs within Hemostasis and Regenerative Medicine. From 2007 to 2008, he was Executive Vice President of MediQuest Therapeutics, Inc., a specialty pharmaceutical company in Bothell, Washington. From 2000 to July 2007, Dr. Öhrström held various positions at ZymoGenetics, Inc., a biotech company, including Senior Vice President, Business Development from 2006 to 2007 and prior to that, Senior Vice President of Development and Chief Medical Officer. From 1990 to 1999, Dr. Öhrström held various positions at Novo Nordisk A/S, based in Denmark, including Director of the Worldwide Development Portfolio. Prior to that, Dr. Öhrström was head of Strategic Marketing at Novo Nordisk, where he led the early launches of Gabitril and NovoSeven. He also served as Medical Director for Novo Nordisk Pharmaceuticals, Inc., located in Princeton, New Jersey. Dr. Öhrström earned his M.D. from the University of Copenhagen in 1984 and did six years of clinical practice in Neurology/Neurosurgery in Sweden and Denmark. During his clinical experience, he served as Clinical Investigator and Assistant Professor.

Stephen G. Dilly, M.B.B.S., Ph.D. joined the Avigen board in 2007.  He has served as CEO of APT Pharmaceuticals of Foster City, California since September 2006.  He graduated as a physician from the University of London in 1982 and received his Ph.D. in Cardiac Physiology from University of London in 1988. Dr. Dilly began his industry career with Pfizer Central Research in the UK in 1986, and since then has held positions of increasing responsibility with Beecham, SmithKline Beecham (VP of CardioPulmonary, VP of Clinical Neuroscience), Genentech (Head of Clinical, Head of Development Sciences) and Chiron BioPharma (SVP Development, Chief Medical Officer). During this career, he has been closely associated with the successful development and launch of a number of important new drugs across many therapeutic areas including Kytril, Paxil CR, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin.